Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011
Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - Q&A: Diaceutics CEO Keeling Provides Personalized Rx-Focused Consultant's View of Industry Progress
February 22, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 4, 2012 / Pharmacogenomics Reporter